| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10215364 | eNeurologicalSci | 2018 | 4 Pages |
Abstract
In conclusion, miRNA 155 could not only be a promising target for the anti-inflammatory therapy in PD but also a good candidate as a disease progression biomarker. The role of levodopa in modulating the levels of miRNA 155 requires further studies.
Related Topics
Life Sciences
Neuroscience
Endocrine and Autonomic Systems
Authors
Elisa Caggiu, Kai Paulus, Giuseppe Mameli, Giannina Arru, Gian Pietro Sechi, Leonardo A. Sechi,